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Abstract
Introduction: Mycosis fungoides (MF), a type of cutaneous T-cell lymphoma, is a rare condition 
with a variety of treatment options. A frequently utilized method in the treatment of early-stage 
MF is phototherapy. Full body phototherapy can be associated with photoaging of the skin and 
an increased risk of developing skin cancer. Targeted phototherapy, with a 308-nm excimer laser, 
may be just as effective and of a lower risk. This makes it especially useful in the treatment of 
patients with dysplastic nevi (DN) or other conditions which can put them at a higher risk of 
developing skin cancer. There are currently limited data on the treatment of early-stage MF with 
an excimer laser.
Case Report: This study reports on a 43-year-old female patient presented to the clinic with 
early-stage (Ia) MF. Given her history of DN, she wished to pursue targeted phototherapy with 
an excimer laser. Localized light treatment was performed via a 308-nm excimer laser, 3 times 
weekly, for a total of 17 treatments to affected lesions. Following excimer laser treatment, she had 
a clinical resolution of her patches. On the follow-up clinic visits, she maintained her excellent 
response 12 months out.
Conclusion: Targeted phototherapy with a 308-nm excimer laser may be a safer and equally 
effective alternative to generalized phototherapy in the treatment of early-stage MF. This case 
report demonstrates its efficacy and advantages over traditional generalized phototherapy.
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Introduction
Mycosis fungoides (MF) is a rare condition with an 
incidence of only six cases per million annually but is 
the most common type of cutaneous T-cell lymphoma.1-3 
Although MF can be present in younger patients, it has 
a peak incidence between the ages of 55 and 60 and is 
twice as common in males.2,4,5 The pathogenesis of MF 
is currently unclear. While environmental exposures and 
infectious causes of MF have been hypothesized, none 
have been confirmed. MF primarily develops in the skin 
but can metastasize to blood, lymph nodes, and visceral 
organs. Affected patients can present with a variety of 
widespread pruritic cutaneous lesions usually involving 
a truncal distribution although any body surface can be 
affected.6,7 Lesions can range from plaques and patches 
to areas of alopecia. They can mimic many dermatologic 
conditions such as eczema, psoriasis, photodermatitis, or 
drug reactions. Both its clinical mimicry and rarity make 
it a challenging diagnosis and one that can be established 
only after obtaining multiple cutaneous biopsies.8
Treatment guidelines for MF vary based on its staging. 
While more advanced stages of the disease may require 
systemic therapy, skin-directed treatments are useful in 
early stages.9 Currently, there are limitations and side 
effects attributed to many of the skin-directed therapies. 
Topical medications can cause hypersensitivity reactions, 
hypopigmentation, skin atrophy, irritant dermatitis, 
pruritus, pain and even hematologic toxicities.10,11 Other 
available options include radiation therapies which expose 
the patient to toxicities and widespread phototherapy, 
placing patients at risk for developing secondary cutaneous 
carcinomas and melanomas.12,13 Data to support targeted 
phototherapies are limited to case reports and case series. 
Excimer lasers, which are composed of noble gases and a 
reactive halogen gas (fluorine or chlorine), operate in the 
ultraviolet (UV) range between 193 and 351 nm.14 They 
are used by clinicians for targeted phototherapy.14 They 
aid in the treatment of psoriasis, vitiligo, atopic dermatitis, 
and alopecia areata; however, there have been only a few 
reports in the treatment of MF with an excimer laser.15-17
Case Presentation
A 43-year-old female with a past medical history of 
dysplastic nevi (DN) and a remote history of early-stage 
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MF presented to the dermatology clinic with slightly 
hyperpigmented patches with a fine scale on her left 
volar forearm, upper left buttock and left posterior thigh. 
Given her history of MF and findings on physical exam, 
MF was suspected. Her MF had been successfully treated 
with narrowband UVB (NB-UVB) 5 years ago. Skin 
biopsy of affected areas confirmed recurrence of her MF, 
and following workup with a clinical lymph node exam, 
complete blood counts and a chemistry panel, she was 
diagnosed with stage 1a MF. She was given and tried using 
a class III topical corticosteroid for 2 months but it was 
discontinued due to irritation and erythema. Alternative 
therapies, namely phototherapy, were considered. 
However, given her history of DN and increased risk of 
melanoma, the patient preferred to use localized light 
treatment rather than NB-UVB. Localized light treatment 
was performed via a 308-nm excimer laser 3 times weekly 
for a total of 17 treatments to her left medial arm, left 
thigh and left calf. Following each tolerated treatment, 
her dose was gradually increased to 1288 mJ/cm2. After 
clinical resolution of her patches, she was monitored on 




Historically, topical treatments have been the mainstay of 
early-stage (Ia-IIa) MF. More recently, with technological 
advances, phototherapies have become a viable option as 
well. Although both of these therapies have been broadly 
studied and proven effective, they do not come without 
side effects.10-13 In patients who cannot tolerate the side 
effects of these therapies, or have contraindications to 
them, alternative options need to be explored.
Traditionally, phototherapies with UVB and PUVA 
have been effective, but because they target both 
pathologic and normal skin, they can increase the 
risk of squamoproliferative skin neoplasms, basal cell 
carcinomas, or melanoma.12,13 It is recommended that 
maintenance phototherapy should not exceed one-
year post remission of MF in order to reduce cutaneous 
carcinogenesis.12,13 Patients on long term phototherapy 
are the most likely to develop skin cancer.18 Unfortunately, 
because maintenance therapy duration is limited, 
the majority of patients will relapse. This scenario 
requires further phototherapy which again can lead to 
carcinogenesis. One useful way to maximize benefit while 
minimizing risk is the usage of targeted phototherapy.
Targeted phototherapy with the 308-nm excimer laser 
can successfully treat early-stage MF while minimizing 
exposure of normal skin to the carcinogenic UV radiation. 
This is especially useful when dealing with a patient 
population who has an increased risk of skin cancer such 
as DN or a long history of sun exposure. An excimer 
laser requires fewer treatments and results in a less toxic 
and cumulative UV dose to healthy skin in comparison 
to generalized phototherapy. It can effectively deliver a 
higher amount of radiation in a shorter period of time to 
only the affected lesions, minimizing treatment duration 
and reducing unnecessary UV exposure and adverse 
effects.19,20 It may also be useful in treating refractory skin 
lesions and difficult to reach anatomical locations.20,21 
Accepted treatment frequency is two to three treatment 
sessions per week, for a total of 10 to 20 treatments, or 
until the lesion is cleared.21 This dosing regimen is used 
at our institution and has resulted in clinical resolution of 
early-stage MF on multiple occasions. We believe when 
clinically appropriate, this may be both superior and less 
damaging to skin than currently utilized therapies.
Conclusion
There are only a limited number of cases that study the 
effectiveness of the 308-nm excimer laser in the treatment 
of early-stage MF.15-17 Generalized phototherapy has been 
well researched and studied, but the efficacy of targeted 
phototherapy with the excimer laser has not been well 
established. As more research is done, it may prove to be 
superior to traditional generalized phototherapy. It has the 
potential to effectively treat MF in a more directed fashion 
while minimizing the potential for carcinogenesis. The 
excimer laser may be especially useful in the treatment 
of MF in patients who have a high risk for cutaneous 
malignancy, as seen in our patient. 
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